Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

b Complications associated with, not necessarily caused by, oral phosphate and active vitamin D treatment.

Source: Tumor removal. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review

Review / evidence synthesis · The Journal of Clinical Endocrinology and Metabolism · 2025

Original publication title

Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review

Suzanne M Jan de Beur; Kathryn M Dahir; Erik A Imel; María Belén Zanchetta; Angela Williams; Zhiyi Li; Neil Webb; Victoria Crowe; Ben Johnson; Thomas O Carpenter

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

TIO is associated with a substantial healthcare resource burden. Improvements in the diagnostic process could lead to better management of TIO, thereby benefiting patients and reducing that burden.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This review aimed to identify published evidence on healthcare resource use in TIO to better understand the burden of the disease.

Source: Objective

Abstract: Context

Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors that secrete fibroblast growth factor 23 (FGF23). Initial signs and musculoskeletal symptoms can be nonspecific and unrecognized, leading to long delays in diagnosis and treatment, and resulting in severe and progressive disability in patients with TIO.

Source: Context

Abstract: Evidence acquisition

A targeted literature review was conducted to identify publications reporting on disease characteristics and healthcare resource use associated with TIO.

Source: Evidence acquisition

Abstract: Evidence synthesis

In total, 414 publications were included in the review, of which 376 were case reports. From the case reports, data on 621 patients were extracted. These patients had a mean (SD) age of 46.3 (15.8) years; 57.6% were male. Mean time from first symptoms to diagnosis of TIO was 4.6 (4.7) years and, in cases where imaging tests were reported, patients underwent a mean of 4.1 (2.7) procedures. Tumor resection was attempted in 81.0% of patients and successful in 67.0%.

Fracture was reported in 49.3% of patients. Results from association analyses demonstrated that longer time to diagnosis was associated with poorer tumor resection outcomes and a higher probability of tumor recurrence. Unfavorable tumor resection outcomes were associated with greater use of pharmacologic treatment and a greater likelihood of orthopedic surgery.

Source: Evidence synthesis

Abstract: Conclusion

TIO is associated with a substantial healthcare resource burden. Improvements in the diagnostic process could lead to better management of TIO, thereby benefiting patients and reducing that burden.

Source: Conclusion
Authors’ abstract

Abstract

Context

Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors that secrete fibroblast growth factor 23 (FGF23). Initial signs and musculoskeletal symptoms can be nonspecific and unrecognized, leading to long delays in diagnosis and treatment, and resulting in severe and progressive disability in patients with TIO.

Objective

This review aimed to identify published evidence on healthcare resource use in TIO to better understand the burden of the disease.

Evidence acquisition

A targeted literature review was conducted to identify publications reporting on disease characteristics and healthcare resource use associated with TIO.

Evidence synthesis

In total, 414 publications were included in the review, of which 376 were case reports. From the case reports, data on 621 patients were extracted. These patients had a mean (SD) age of 46.3 (15.8) years; 57.6% were male. Mean time from first symptoms to diagnosis of TIO was 4.6 (4.7) years and, in cases where imaging tests were reported, patients underwent a mean of 4.1 (2.7) procedures. Tumor resection was attempted in 81.0% of patients and successful in 67.0%.

Fracture was reported in 49.3% of patients. Results from association analyses demonstrated that longer time to diagnosis was associated with poorer tumor resection outcomes and a higher probability of tumor recurrence. Unfavorable tumor resection outcomes were associated with greater use of pharmacologic treatment and a greater likelihood of orthopedic surgery.

Conclusion

TIO is associated with a substantial healthcare resource burden. Improvements in the diagnostic process could lead to better management of TIO, thereby benefiting patients and reducing that burden.

Publication and source details

Original title: Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review

Suzanne M Jan de Beur; Kathryn M Dahir; Erik A Imel; María Belén Zanchetta; Angela Williams; Zhiyi Li; Neil Webb; Victoria Crowe; Ben Johnson; Thomas O Carpenter

The Journal of Clinical Endocrinology and Metabolism · 2025

Correspondence: Ben Johnson, MSc, Department of Health Economics and Outcomes Research, Kyowa Kirin International plc, 2 Globeside, Fieldhouse Lane, Marlow, Buckinghamshire, SL7 1HZ, UK. Email: ben.johnson@kyowakirin.com.© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.2024https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. Kyowa Kirin International

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T08:13:15.105567+00:00

DOI: 10.1210/clinem/dgae431 · PMC11651676